Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 4, 2010 Ryan McBride	Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share.
The Motley Fool July 26, 2010 Ryan McBride	How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis
The Motley Fool August 30, 2010 Ryan McBride	Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
The Motley Fool July 23, 2009 Brian Orelli	This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme
Pharmaceutical Executive March 1, 2006 Sara Calabro	Genzyme: The Price of Success Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism.
The Motley Fool July 18, 2005 Stephen D. Simpson	Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky.
The Motley Fool January 26, 2005 John Bluis	Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease.
Pharmaceutical Executive September 1, 2008 Jeffrey S. Aronin	The Orphan Opportunity The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains
The Motley Fool September 11, 2010 Luke Timmerman	Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce.
The Motley Fool October 22, 2009 Brian Orelli	The Gift That Keeps on Giving Genzyme's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, its stock is still dealing with the aftermath.
The Motley Fool May 14, 2010 Ryan McBride	Genzyme in "Tough Spot" With Icahn Proxy Challenge Carl Icahn is pushing for change, but Genzyme's CEO has been pushing back.
BusinessWeek April 22, 2010 Rob Waters	Gene Therapy Takes a Turn for the Better Researchers and investors are heartened by advances in gene therapy. Analysts say revenues are still several years off, however.
The Motley Fool September 13, 2010 Brian Orelli	When All Else Fails, Sell! Genzyme has no other choice.
The Motley Fool January 9, 2008 Brian Orelli	Genzyme Buys Into Antisense RNA -- Big Time Genzyme buys a piece of Isis' mipomersen at a wowser of a price.
The Motley Fool February 12, 2009 Brian Orelli	Cruising, but Ready to Take Off Genzyme's in wait-and-see mode.
Managed Care February 2005 Mark Zitter	Managing Drugs for Rare Genetic Diseases: Trends and Insights Evaluates recent trends and challenges in health system management of exceedingly rare genetic diseases, from the perspective of the manufacturer, managed care organization, physician, and actuary.
The Motley Fool June 21, 2005 Charly Travers	A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire.
The Motley Fool March 2, 2004 David Nierengarten	Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines.
The Motley Fool February 3, 2010 Brian Orelli	Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease.
The Motley Fool February 17, 2011 Brian Orelli	What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate.
The Motley Fool July 12, 2006 Brian Lawler	Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share.
The Motley Fool November 19, 2009 Brian Orelli	This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous.
Chemistry World January 26, 2015 Phillip Broadwith	Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion.
The Motley Fool November 24, 2010 Brian Orelli	Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant.
The Motley Fool December 1, 2009 Brian Orelli	Pfizer Takes In an Orphan on the Cheap Steal is a pretty accurate term for the price Pfizer paid for Protalix BioTherapeutics' taliglucerase alfa.
The Motley Fool February 24, 2005 Charly Travers	Transkaryotic's Turnaround This biotech spotlights superb management creating shareholder value.
The Motley Fool October 28, 2010 Brian Orelli	This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37.
The Motley Fool October 4, 2010 Brian Orelli	That's No Way to Make Friends Sanofi goes hostile on Genzyme.
The Motley Fool July 26, 2010 Brian Orelli	Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete?
The Motley Fool January 21, 2010 Brian Orelli	The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments.
The Motley Fool September 25, 2009 Brian Orelli	Genzyme's Good News. Finally! It's been awhile, hasn't it?
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
Chemistry World September 11, 2012 Maria Burke	Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool July 7, 2010 Brian Orelli	That's Gotta Hurt: Recommending the Competition Supply constraints continue to plague Genzyme.
The Motley Fool November 18, 2010 Brian Orelli	Genzyme: Slimmed Down, Gussied Up But will anyone buy it?
Managed Care September 2004 Thomas Morrow	Orphan Drug Act Treatments Deserve Full Insurance Coverage An important federal law encourages development of drugs for populations so small that the market would otherwise ignore them. Should they not then be covered?
The Motley Fool June 21, 2010 Erin Kutz	Curis Misses Mark in Drug Trial; Genzyme Elects Board; GTC Cuts Jobs; and More Boston-Area Life Sciences News These drug and biomedical companies made news last week.
The Motley Fool October 21, 2010 Brian Orelli	Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track.
The Motley Fool September 14, 2006 Brian Lawler	Close Failure for Genzyme Will Genzyme's Campath get approval? Investors shouldn't hold their breath.
Pharmaceutical Executive October 1, 2005 Brad Miles	Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies.
The Motley Fool August 20, 2010 Brian Orelli	This Billionaire Likes Biotech. Should You? It depends on how much you trust management.
The Motley Fool April 20, 2006 John Bluis	Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management.
The Motley Fool February 23, 2009 Brian Orelli	Genzyme Playing Defense The latest good news from this company won't help the top line much.
Chemistry World November 11, 2013 Phillip Broadwith	Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.